Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment
Open Access
- 18 March 2008
- journal article
- research article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 8 (6) , 391-399
Abstract
We evaluated the cost-effectiveness of a range of smoking cessation drug treatments, including varenicline, transdermal nicotine (TN), bupropion and the use of a genetic test to choose between TN and bupropion. We performed Monte Carlo simulation with sensitivity analysis, informing analyses with published estimates of model parameters and current prices for genetic testing and smoking-cessation therapy. The primary outcomes were discounted life-years (LY) and lifetime tobacco-cessation treatment costs. In the base case, varenicline treatment was optimal with an ICER, compared to bupropion, of $2985/LY saved. In sensitivity analyses, varenicline was in all cases (and bupropion in most cases) admissible; only under favorable assumptions was the genetically tailored approach competitive. Our data suggest that an untailored approach of treatment with either bupropion or varenicline is a cost-effective form of tobacco dependence treatment, but a tailored approach for selecting between TN and bupropion can be cost-effective under plausible assumptions.Keywords
This publication has 57 references indexed in Scilit:
- Nicotine replacement therapy for long-term smoking cessation: a meta-analysisTobacco Control, 2006
- Symbiotic relationship of pharmacogenetics and drugs of abuseThe AAPS Journal, 2006
- Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapyMolecular Psychiatry, 2006
- Role of Functional Genetic Variation in the Dopamine D2 Receptor (DRD2) in Response to Bupropion and Nicotine Replacement Therapy for Tobacco Dependence: Results of Two Randomized Clinical TrialsNeuropsychopharmacology, 2005
- Mortality in relation to smoking: 50 years' observations on male British doctorsBMJ, 2004
- Association of Short-Term Response to Haloperidol Treatment With a Polymorphism in the Dopamine D2 Receptor GeneAmerican Journal of Psychiatry, 2001
- A propensity analysis of cigarette smoking and mortality with consideration of the effects of alcohol∗∗Note: This study uses data supplied by the National Heart, Lung, and Blood Institute, National Institutes of Health, United States Department of Health and Human Services, Bethesda, Maryland. The views expressed in this study are those of the authors and do not necessarily reflect the views of the National Heart, Lung, and Blood Institute.The American Journal of Cardiology, 2001
- Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectivenessThe Lancet, 1999
- Predictors of smoking cessation in a cohort of adult smokers followed for five yearsTobacco Control, 1997
- The Cost-Effectiveness of the Nicotine Transdermal Patch for Smoking CessationPreventive Medicine, 1997